Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials

American Journal of Surgical Pathology

Volumn 36, Issue 7, 2012, Pages 945-954

  Jordan, Richard C ^a   Lingen, Mark W ^b   Perez Ordonez, Bayardo ^c   He, Xin ^d   Pickard, Robert ^e   Koluder, Michael ^e   Jiang, Bo ^e   Wakely, Paul ^f   Xiao, Weihong ^e   Gillison, Maura L ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF MARYLAND   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

HPV; oropharyngeal carcinoma; p16; scoring

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; FIXATIVE; FORMALDEHYDE; MESSENGER RNA; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PARAFFIN; PROTEIN E7; REPRESSOR PROTEIN; TUMOR MARKER; VIRUS DNA; VIRUS RNA;

ARTICLE; CHEMISTRY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL (TOPIC); COOPERATION; FEASIBILITY STUDY; FEMALE; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MALE; METABOLISM; METHODOLOGY; OBSERVER VARIATION; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TISSUE FIXATION; UNITED STATES; VALIDATION STUDY; VIROLOGY; VIRUS LOAD;

CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEASIBILITY STUDIES; FEMALE; FIXATIVES; FORMALDEHYDE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; OBSERVER VARIATION; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; VIRAL LOAD;

EID: 84863302564     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318253a2d1     Document Type: Article

References (35)

1. Ahmed A, Cascarini L, Sandison A, et al. Survey of the use of tests for human papilloma virus and epidermal growth factor receptor for squamous cell carcinoma of the head and neck in UK head and neck multidisciplinary teams. Br J Oral Maxillofac Surg. 2011;3:1-5.
2. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
3. Begum S, Gillison ML, Ansari-Lari MA, et al. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res. 2003;9:6469-6475. (Pubitemid 38031835)
4. Begum S, Gillison ML, Nicol TL, et al. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:1186-1191. (Pubitemid 46424059)
5. Cantley RL, Gabrielli E, Montebelli F, et al. Ancillary studies in determining human papillomavirus status of squamous cell carcinoma of the oropharynx: a review. Pathol Res Int. 2011; 1-7.
6. Cao D, Begum S, Ali SZ, et al. Expression of p16 in benign and malignant cystic squamous lesions of the neck. Hum Pathol. 2010;41:535-539.
7. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100: 261-269. (Pubitemid 351480538)
8. Gillison M. HPV and its effect on head and neck cancer prognosis. Clin Adv Hematol Oncol. 2010;8:680-682.
9. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407-420. (Pubitemid 351480511)
10. Huang CC, Qiu JT, Kashima ML, et al. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol. 1998;11:971-977. (Pubitemid 28487217)
11. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001;92:276-284. (Pubitemid 32225381)
12. Kudahetti SC, Fisher G, Ambroisine L, et al. Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. Pathology. 2010;42:519-523.
13. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPVassociated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1992-1998.
14. Lewis JS Jr, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 2010;34:1088-1096.
15. Liu D, Nakano J, Ueno M, et al. A useful protocol for analyses of mutations of the epidermal growth factor receptor gene. Oncol Rep. 2006;15:1503-1505.
16. Park JM, Jung CK, Choi YJ, et al. The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma. Hum Pathol. 2010;41:431-437.
17. Perez-Sayans M, Suarez-Penaranda JM, Gayoso-Diz P, et al. p16(INK4a)/CDKN2 expression and its relationship with oral squamous cell carcinoma is our current knowledge enough? Cancer Lett. 2011;306:134-141.
18. Perrone F, Gloghini A, Cortelazzi B, et al. Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. Am J Surg Pathol. 2011;35:774-777.
19. Pfister DG, Ang KK, Brizel DM, et al. Head and neck cancers. J Natl Compr Cancer Netw. 2011;9:596-650.
20. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22: 1071-1074.
21. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010;28:4142-4148.
22. Romagosa C, Simonetti S, Lopez-Vicente L, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30:2087-2097.
23. Schlecht NF, Brandwein-Gensler M, Nuovo GJ, et al. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol. 2011;24:1295-1305.
24. Schmidt D, Bergeron C, Denton KJ, et al. p16/ki-67 dual-Stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the european equivocal or mildly abnormal papanicolaou cytology study. Cancer Cytopathol. 2011;119:158-166.
25. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27:6213-6221.
26. Shoushtari AN, Rahimi NP, Schlesinger DJ, et al. Survey on human papillomavirus/p16 screening use in oropharyngeal carcinoma patients in the United States. Cancer. 2010;116:514-519.
27. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010;116:2166-2173.
28. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007;121:2465-2472. (Pubitemid 350022416)
29. Thavaraj S, Stokes A, Guerra E, et al. Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol. 2011;64:308-312.
30. Tong J, Sun X, Cheng H, et al. Expression of p16 in non-small cell lung cancer and its prognostic significance: A meta-analysis of published literatures. Lung Cancer. 2011;74:155-163.
31. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009;35:210-220.
32. Ukpo OC, Flanagan JJ, Ma XJ, et al. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol. 2011;35:1343-1350.
33. van Houten VM, Snijders PJ, van den Brekel MW, et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer. 2001;93:232-235. (Pubitemid 32574279)
34. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24:736-747. (Pubitemid 46622040)
35. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008;26:3138-3146.